| Curtis Boardman, CRNA | |
|
129 W Lake Mead Pkwy, B 18, Henderson, NV 89015-7055 | |
| (702) 564-4440 | |
| (702) 558-1522 |
| Full Name | Curtis Boardman |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 23 Years |
| Location | 129 W Lake Mead Pkwy, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265424428 | NPI | - | NPPES |
| 100504172 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | CRNA000256 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allegiant Institute Inc | 4981678695 | 19 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
Researchers at Sydney's Centenary Institute have discovered new information about the cornea which could lead to vital new treatments aimed at repairing vision impairment and blindness.
The Research & Development Council of New Jersey will honor the winners of the 2015 Edison Patent Awards at the 36th Edison Patent Awards Ceremony & Reception on November 12, 2015. Over 50 inventors and 12 New Jersey companies and universities will be recognized at the event.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.
A pathway known for its role in regulating adult stem cells has been shown to be important for hair follicle proliferation, but contrary to previous studies, is not required within hair follicle stem cells for their survival, according to researchers with the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
| Entity Name | Allegiant Institute Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932264439 PECOS PAC ID: 4981678695 Enrollment ID: O20040819001141 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
Researchers at Sydney's Centenary Institute have discovered new information about the cornea which could lead to vital new treatments aimed at repairing vision impairment and blindness.
The Research & Development Council of New Jersey will honor the winners of the 2015 Edison Patent Awards at the 36th Edison Patent Awards Ceremony & Reception on November 12, 2015. Over 50 inventors and 12 New Jersey companies and universities will be recognized at the event.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.
A pathway known for its role in regulating adult stem cells has been shown to be important for hair follicle proliferation, but contrary to previous studies, is not required within hair follicle stem cells for their survival, according to researchers with the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Curtis Boardman, CRNA 129 W Lake Mead Pkwy, B 18, Henderson, NV 89015-7055 Ph: (702) 564-4440 | Curtis Boardman, CRNA 129 W Lake Mead Pkwy, B 18, Henderson, NV 89015-7055 Ph: (702) 564-4440 |
News Archive
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
Researchers at Sydney's Centenary Institute have discovered new information about the cornea which could lead to vital new treatments aimed at repairing vision impairment and blindness.
The Research & Development Council of New Jersey will honor the winners of the 2015 Edison Patent Awards at the 36th Edison Patent Awards Ceremony & Reception on November 12, 2015. Over 50 inventors and 12 New Jersey companies and universities will be recognized at the event.
Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules, 5mg, 10mg, 15mg & 20mg. Focalin XR is manufactured for the U.S. for Novartis Pharmaceuticals Corporation by Elan Holdings Inc.
A pathway known for its role in regulating adult stem cells has been shown to be important for hair follicle proliferation, but contrary to previous studies, is not required within hair follicle stem cells for their survival, according to researchers with the Perelman School of Medicine at the University of Pennsylvania.
› Verified 4 days ago
Jaime Parke, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 129 W Lake Mead Pkwy, Suite B18, Henderson, NV 89015 Phone: 702-564-4440 Fax: 702-558-1522 | |
Akimi S Mcknight, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 129 W Lake Mead Pkwy, B18, Henderson, NV 89015 Phone: 702-564-4440 Fax: 702-558-1522 | |
Natalie J Lewis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 129 W Lake Mead Pkwy, #b-18, Henderson, NV 89015 Phone: 702-564-4440 Fax: 702-558-1522 | |
Heather Wiley Suescun, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 129 W Lake Mead Pkwy, #b-18, Henderson, NV 89015 Phone: 702-564-4440 Fax: 702-558-1522 | |
Matthew Lee Rigby, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 129 W Lake Mead Pkwy, Suite B18, Henderson, NV 89015 Phone: 702-564-4440 | |
Mr. Michael Douglas Dixon, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 129 W Lake Mead Pkwy, Suite B-18, Henderson, NV 89015 Phone: 702-564-4440 |